Morphine in Children with Cancer

REFERENCES

• Martindale. The complete drug reference. Thirty second ed. Pharmaceutical Press. 1999
   Google Scholar
• WHO. World Health Organisation. Cancer Pain Relief Program. GenevaSwitzerland 1986
   Google Scholar
• International Narcotic Control Board. Narcotic Drugs: Estimated World Requirements for 1995. 1995, Statistics for 1993. United Nation
   Google Scholar
• Hain R D, Miser A, Devins M, Wallace W H. Strong opioids in pédiatrie palliative medicine. Paediatr Drugs 2005; 7(1)1–9
   Google Scholar
• Ganshorn A, Kurz H. [Differences between the protein binding of newborns and adults and their importance for pharmacological action]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1968; 260(2)117–8
   PubMedGoogle Scholar
• Hollt V, Teschemacher H. Hydrophobic interactions responsible for unspecific binding of morphine-like drugs. Naunyn Schmiedebergs Arch Pharmacol 1975; 288(2–3)163–77
   Google Scholar
• Judis J. Binding of codeine, morphine, and methadone to human serum proteins. J Pharm Sci 1977; 66(6)802–6
   Google Scholar
• Leow K P, Wright A W, Cramond T, Smith M T. Determination of the serum protein binding of oxy-codone and morphine using ultrafiltration. Ther Drug Monit 1993; 15(5)440–7
   Google Scholar
• Milne R W, Nation R L, Somogyi A A, Bochner F, Griggs W M. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol 1992; 34(1)53–9
   Google Scholar
• Olsen G D. Morphine binding to human plasma proteins. Clin Pharmacol Ther 1975; 17(1)31–5
   PubMed Web of Science ®Google Scholar
• Poyhia R, Seppala T. Liposolubility and protein binding of oxycodone in vitro. Pharmacol Toxicol 1994; 74(1)23–7
   PubMedGoogle Scholar
• Raveendran R, Heybroek W M, Caulfield M, Abrams S M, Wrigley P F, Slevin M, et al. Protein binding of indomethacin, methotrexate and morphine in patients with cancer. Int J Clin Pharmacol Res 1992; 12(3)117–22
   Google Scholar
• Stain-Texier F, Boschi G, Sandouk P, Scherrmann J M. Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br J Pharmacol 1999; 128(4)917–24
   Google Scholar
• Vree T B, Verwey-van Wissen C P. Pharma-cokinetics and metabolism of codeine in humans. BiopharmDrug Dispos 1992b; 13(6)445–60
   PubMed Web of Science ®Google Scholar
• Rowland M, Tozer T. Clinical Pharmacokinetics Concepts and Applications. Third ed. Lippincott Williams and Wilkins, Philadelphia 1995
   Google Scholar
• Charles M A, Fontbonne A, Thibult N, Claude J R, Warnet J M, Rosselin G, et al. High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris Prospective Study. Am J Epidemiol 2001; 153(3)292–8
   Google Scholar
• Birkett D J. The importance of unbound drug. Agents Actions Suppl 1985; 17: 79–84
   Google Scholar
• Routledge P A. The plasma protein binding of basic drugs. Br J Clin Pharmacol 1986; 22(5)499–506
   PubMed Web of Science ®Google Scholar
• Spector A A, Santos E C, Ashbrook J D, Fletcher J E. Influence of free fatty acid concentration on drug binding to plasma albumin. Ann N Y Acad Sci 1973; 226: 247–58
   PubMedGoogle Scholar
• Coyle D E, Denson D D, Essell S K, Santos D J. The effect of nonesterified fatty acids and progesterone on bupivacaine protein binding. Clin Pharmacol Ther 1986; 39(5)559–63
   Google Scholar
• Goldman A, Hewitt M, Collins G S, Childs M, Hain R. Symptoms in children/young people with progressive malignant disease: United Kingdom Children's Cancer Study Group/Paediatric Oncology Nurses Forum survey. Pediatrics 2006; 117(6)179–86
   Google Scholar
• Mashayekhi S. Studies on the disposition of morphine and morphine 6-glucuronide with particular reference to children. Cardiff, Cardiff 2004
   Google Scholar
• D'Honneur G, Gilton A, Sandouk P, Scherrmann J M, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 1994; 81(1)87–93
   PubMed Web of Science ®Google Scholar
• Hasselstrom J, Alexander N, Bringel C, Svensson J O, Sawe J. Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients-a comparison of two oral formulations. Eur J Clin Pharmacol 1991; 40(6)585–91
   Google Scholar
• Manara A R, Shelly M P, Quinn K G, Park G R. Pharmacokinetics of morphine following administration by the buccal route. Br J Anaesth 1989; 62(5)498–502
   Google Scholar
• Poulain P, Hoskin P J, Hanks G WOAO, Walker V A, Johnston A, et al. Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. Br J Anaesth 1988; 61(5)569–74
   Google Scholar
• Combe B, Edno L, Lafforgue P, Bologna C, Bernard J C, Acquaviva P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol 1995; 34(5)421–8
   Google Scholar
• Crom W R, de Graaf S S, Synold T, Uges D R, Bloemhof H, Rivera G, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994; 125(4)642–9
   PubMed Web of Science ®Google Scholar
• de Lannoy I A, Mandin R S, Silverman M. Renal secretion of vinblastine, vincristine and colchicine in vivo. J Pharmacol Exp Ther 1994; 268(1)388–95
   Google Scholar
• Dollery C T. Therapeutic Drugs. 2 ed. Churchill Livingstone, OxfordUK 1999
   Google Scholar
• Sethi V S, Jackson D V, Jr., White D R, Richards F, 2nd, Stuart J J, Muss H B, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 1981; 41(9Ptl)3551–5
   Google Scholar
• Sethi V S, Kimball J C. Pharmacokinetics of vincristine sulfate in children. Cancer Chemother Pharmacol 1981; 6(2)111–5
   Google Scholar
• Sjoholm I, Stjerna B. Binding of drugs to human serum albumin XVII: Irreversible binding of merca-ptopurine to human serum proteins. J Pharm Sci 1981; 70(11)1290–1
   Google Scholar
• Skibinska L, Ramlau C, Zaluski J, Olejniczak B. Methotrexate binding to human plasma proteins. Pol J Pharmacol Pharm 1990; 42(2)151–7
   Google Scholar
• Abbott F V, Palmour R M. Morphine-6-glucur-onide: analgesic effects and receptor binding profile in rats. Life Sci 1988; 43(21)1685–95
   Google Scholar
• Pasternak G W, Bodnar R J, Clark J A, Inturrisi C E. Morphine-6-glucuronide, a potent mu agonist. Life Sci 1987; 41(26)2845–9
   PubMed Web of Science ®Google Scholar
• Paul D, Standifer K M, Inturrisi C E, Pasternak G W. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251(2)477–83
   PubMed Web of Science ®Google Scholar
• Hain R DW, Hardcastle A, Pinkerton C R, Aherne G W. Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. Br J Clin Pharmacol 1999; 48: 37–42
   PubMed Web of Science ®Google Scholar
• Hunt A M, Joel S, Dick G, Goldman A. Population pharmacokinetics of oral morphine and its glucuro-nides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. The Journal of Pediatrics 1999; 135(1)47–55
   PubMed Web of Science ®Google Scholar
• Hunt A M, Joel S, Gloyn A, Goldman A. Establishing pharmacokinetics of oral morphine liquid and its glucuronides in children with cancer. < None Specified> 1996; 394
   Google Scholar
• Nilsen O G, Leren P, Aakesson I, Jacobsen S. Binding of quinidine in sera with different levels of tri-glycérides, cholesterol, and orosomucoid protein. Biochem Pharmacol 1978; 27(6)871–6
   Google Scholar
• Guentert T W, Frey B M, Luedin E, Heinzl S, Brodersen R. Increase of plasma nonesterified fatty acid concentration and decrease of albumin binding affinity after intravenous injection of glycocholate-lecithin mixed micelles. J Lab Clin Med 1990; 116(1)66–75
   Google Scholar
• Lerman J, Strong H A, LeDez K M, Swartz J, Rieder M J, Burrows F A. Effects of age on the serum concentration of alpha 1-acid glycoprotein and the binding of lidocaine in pédiatrie patients. Clin Pharmacol Ther 1989; 46(2)219–25
   PubMed Web of Science ®Google Scholar
• McNamara P J, Alcorn J. Protein binding predictions in infants. AAPS PharmSci 2002; 4(1)E4
   PubMedGoogle Scholar
• Pacifici G M, Bencini C, Rane A. Presystemic glucuronidation of morphine in humans and rhesus monkeys: subcellular distribution of the UDP-glucuro-nyltransferase in the liver and intestine. Xenobiotica 1986; 16(2)123–8
   Web of Science ®Google Scholar
• Rutkowski R B. Bilirubin binding by primary sites of human serum albumin, with suppression of secondary-site interference by use of a high salt concentration. ClinChem 1980; 26(1)107–10
   Google Scholar
• Wilson A S, Stiller R L, Davis P J, Fedel G, Chakravorti S, Israel B A, et al. Fentanyl and alfentanil plasma protein binding in preterm and term neonates. Anesth Analg 1997; 84(2)315–8
   PubMed Web of Science ®Google Scholar
• Wood M, Wood A J. Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther 1981; 29(4)522–6
   Google Scholar
• Tiula E, Tallgren L G, Neuvonen P J. Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases. Int J Clin Pharmacol Ther Toxicol 1987; 25(10)545–52
   Google Scholar
• Jaume J C, Mendel C M, Frost P H, Greenspan F S, Laughton C W. Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis. Thyroid 1996; 6(2)79–83
   PubMed Web of Science ®Google Scholar
• Nozaka T. [The influence of heparin administration on the plasma protein binding of lidocaine during epidural anesthesia]. Masui 1992; 41(3)390–400
   Google Scholar